Company intelligence / Profile preview

Bectas Therapeutics Inc.

Houston, Texas, United Statesbectastx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Bectas Therapeutics has demonstrated profound preclinical efficacy with its monoclonal antibody programs. These programs modulate the tumor immune microenvironment and are accompanied by unique biomarkers to identify patients most likely to benefit. The company’s approach aims to increase clinical success rates and reduce development time and cost by focusing on precision patient selection using human-derived biomarker insights. No clinical trial results have been reported as of May 2025.

Therapeutic areas: Oncology
Modalities: monoclonal antibodies
Industry: Biotech

Beyond the preview

Go deeper on Bectas Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bectas Therapeutics Inc..

Explore the full profile